Literature DB >> 19523942

Astrocytoma derived short-term cell cultures retain molecular signatures characteristic of the tumour in situ.

Nicola E Potter1, K Phipps, W Harkness, R Hayward, D Thompson, T S Jacques, B Harding, D G T Thomas, J Rees, J L Darling, T J Warr.   

Abstract

The heterogeneity of tumours and uncertainties surrounding derived short-term cell cultures and established cell lines fundamentally challenge the research and understanding of tumour growth and development. When tumour cells are cultured, changes are inevitably induced due to the artificial growth conditions. Several recent studies have questioned how representative established cell lines or derived short-term cell cultures are of the tumour in situ. We have characterised gene expression changes induced by short-term culture in astrocytoma in order to determine whether derived short-term cell cultures are representative of the tumour in situ. In comparison to the majority of studies, paired biopsies and derived short-term cultures were investigated to reduce the effects of long-term culture and inter-tumour variability when comparing biopsies and derived cultures from tumours with the same histology from different individuals. We have used the Affymetrix GeneChip U133A to generate gene expression profiles of 6 paediatric pilocytic astrocytoma (PA) biopsies and derived short-term cell cultures and 3 adult glioblastoma multiforme (GBM) biopsies and derived short-term cultures. Significant differential gene expression is induced by short-term culture. However, when the biopsy and derived short-term cell culture samples were grouped according to tumour type (PA and GBM) a molecular signature of 608 genes showed significant differential expression between the groups. This gene cohort can distinguish PA and GBM tumours, regardless of the sample source, suggesting that astrocytoma derived short-term cultures do retain key aspects of the global tumour expression profile and are representative of the tumour in situ. Furthermore, these genes are involved in pathways and functions characteristic of adult GBM including VEGF signalling, hypoxia and TP53 signalling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19523942     DOI: 10.1016/j.yexcr.2009.06.003

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  5 in total

1.  Identification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomics.

Authors:  François Autelitano; Denis Loyaux; Sébastien Roudières; Catherine Déon; Frédérique Guette; Philippe Fabre; Qinggong Ping; Su Wang; Romane Auvergne; Vasudeo Badarinarayana; Michael Smith; Jean-Claude Guillemot; Steven A Goldman; Sridaran Natesan; Pascual Ferrara; Paul August
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

2.  Astrocytoma-associated antigens - IL13Rα2, Fra-1, and EphA2 as potential markers to monitor the status of tumour-derived cell cultures in vitro.

Authors:  Monika Witusik-Perkowska; Magdalena Zakrzewska; Malgorzata Szybka; Wielislaw Papierz; Dariusz J Jaskolski; Pawel P Liberski; Beata Sikorska
Journal:  Cancer Cell Int       Date:  2014-08-22       Impact factor: 5.722

Review 3.  Role of Microenvironment in Glioma Invasion: What We Learned from In Vitro Models.

Authors:  Ivana Manini; Federica Caponnetto; Anna Bartolini; Tamara Ius; Laura Mariuzzi; Carla Di Loreto; Antonio Paolo Beltrami; Daniela Cesselli
Journal:  Int J Mol Sci       Date:  2018-01-04       Impact factor: 5.923

Review 4.  Glioma: experimental models and reality.

Authors:  Krissie Lenting; Roel Verhaak; Mark Ter Laan; Pieter Wesseling; William Leenders
Journal:  Acta Neuropathol       Date:  2017-01-10       Impact factor: 17.088

5.  Artificial microenvironment of in vitro glioblastoma cell cultures changes profile of miRNAs related to tumor drug resistance.

Authors:  Monika Witusik-Perkowska; Magdalena Zakrzewska; Dariusz J Jaskolski; Pawel P Liberski; Janusz Szemraj
Journal:  Onco Targets Ther       Date:  2019-05-20       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.